Harrow, Inc. (HROW) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Harrow, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.057 Good morning, and welcome to HARO's first quarter 2025 earnings conference call. 00:00:05.057 -- 00:00:08.481 My name is Shannon, and I will be your operator for today's call. 00:00:08.481 -- 00:00:11.705 At this time, all participants are in a listen-only mode. 00:00:11.705 -- 00:00:14.829 Later, we will conduct a question and answer session. 00:00:14.829 -- 00:00:17.553 As a reminder, this conference is being recorded. 00:00:17.553 -- 00:00:20.937 I would now like to turn the call over to Jamie Webb, Director of Communications and 00:00:20.937 -- 00:00:23.758 Investor Relations for HARO. 00:00:24.281 -- 00:00:29.783 Thank you, operator. Good morning and welcome to HAREL's first quarter 2025 earnings 00:00:29.783 -- 00:00:34.829 conference call. Before we begin today, let me remind you that the company's remarks 00:00:34.829 -- 00:00:39.875 may include forward-looking statements within the meaning of federal securities law. 00:00:39.875 -- 00:00:44.000 Forward-looking statements are subject to numerous risk and uncertainty, many of which 00:00:44.000 -- 00:00:48.726 are beyond HAREL's control, including risk and uncertainties described from time to time 00:00:48.726 -- 00:00:53.632 in its SEC filings, such as the risk and uncertainties related to the company's ability 00:00:53.632 -- 00:00:59.251 to make commercially available its FDA-approved products and compounded formulations 00:00:59.251 -- 00:01:04.516 and technologies, and FDA approval of certain drug candidates in a timely manner 00:01:04.516 -- 00:01:06.298 are at all. 00:01:06.298 -- 00:01:10.742 For a list and description of those risks and uncertainties, please see the risk factors 00:01:10.742 -- 00:01:15.847 section of the company's most recent annual report on Form ...